Table 3.
Association between Advance Care Planning and Quality End-of-life Care
| Metrics | Adjusted RR (95% CI) | P Value | |
|---|---|---|---|
|
| |||
| Hospital admission | AD only vs. no-ACP | 0.92 (0.78-1.09) | 0.33 |
| DPOA only vs. no-ACP | 0.98 (0.86-1.12) | 0.82 | |
| Discussion only vs. no-ACP | 1.05 (0.96-1.15) | 0.26 | |
|
| |||
| In-hospital death | AD only vs. no-ACP | 0.86 (0.73-1.01) | 0.07 |
| DPOA only vs. no-ACP | 0.88 (0.78-1.00) | 0.05 | |
| Discussion only vs. no-ACP | 1.02 (0.92-1.14) | 0.64 | |
|
| |||
| > 14 days in hospital | AD only vs. no-ACP | 0.31 (0.13-0.73) | 0.008 |
| DPOA only vs. no-ACP | 0.96 (0.67-1.39) | 0.84 | |
| Discussion only vs. no-ACP | 0.97 (0.77-1.22) | 0.77 | |
|
| |||
| ICU admission | AD only vs. no-ACP | 0.81 (0.55-1.18) | 0.26 |
| DPOA only vs. no-ACP | 0.90 (0.72-1.14) | 0.38 | |
| Discussion only vs. no-ACP | 1.02 (0.90-1.17) | 0.72 | |
|
| |||
| > 1 ED visits | AD only vs. no-ACP | 1.04 (0.65-1.66) | 0.87 |
| DPOA only vs. no-ACP | 0.97 (0.71-1.34) | 0.87 | |
| Discussion only vs. no-ACP | 0.89 (0.70-1.13) | 0.33 | |
|
| |||
| Hospice admission | AD only vs. no-ACP | 1.67 (1.20-2.33) | 0.003 |
| DPOA only vs. no-ACP | 1.40 (1.12-1.76) | 0.004 | |
| Discussion only vs. no-ACP | 1.48 (1.24-1.76) | <0.001 | |
|
| |||
| Length of hospice stay ≤ 3 days | AD only vs. no-ACP | 0.88 (0.78-0.99) | 0.03 |
| DPOA only vs. no-ACP | 0.93 (0.88-0.99) | 0.02 | |
| Discussion only vs. no-ACP | 0.92 (0.87-0.96) | 0.001 | |
RR = relative risk, AD = advance directive, ACP = advance care planning, DPOA = durable power of attorney, ICU = intensive care unit, ED = emergency department
Relative Risk was estimated by Poisson regression with point and variance estimates by using jackknife replication method.
Reported values incorporate survey weights to account for the complex survey design.
Covariates include demographic characteristics (age at death, gender, race/ethnicity, married/partnered status, net worth, year of death) and medical comorbidities (cancer, hypertension, diabetes, lung diseases, heart diseases, stroke, and cognitive impairment).